PG
RARE icon

PEAK6 Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

PEAK6 Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,300
Closed -$60K – 4821
2017
Q4 		$60K Buy
1,300
+200
+18% +$9.81K ﹤0.01% 3712
2017
Q3 		$59K Buy
+1,100
New +$65.2K ﹤0.01% 3953
2017
Q2 		– Sell
-3,784
Closed -$256K – 4921
2017
Q1 		$256K Buy
+3,784
New +$288K ﹤0.01% 2861
2015
Q4 		– Sell
-10,350
Closed -$997K – 5197
2015
Q3 		$997K Buy
+10,350
New +$1.19M 0.01% 2193

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PEAK6 Group's RARE Position: Q1 2018 in Review

PEAK6 Group sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2018, closing a stake of 1,300 shares — an estimated $60K sold.

PEAK6 Group first reported a position in RARE in Q3 2015 and held it in 4 quarters. The position peaked at $997K in Q3 2015. 165 funds tracked by Wall St. Rank hold RARE as of Q1 2018.

  • PEAK6 Group reported no remaining Ultragenyx Pharmaceutical position as of Q1 2018 after selling out during the quarter.
  • PEAK6 Group sold 1,300 Ultragenyx Pharmaceutical shares in Q1 2018, an estimated $60K.
  • PEAK6 Group first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 4 quarters.
  • PEAK6 Group's Ultragenyx Pharmaceutical position peaked at $997K in Q3 2015.
  • 165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2018.

Based on PEAK6 Group's 13F filing for Q1 2018, filed 15 May 2018.